Bone marrow mesenchymal stem cells inhibit cardiac hypertrophy by enhancing FoxO1 transcription
- PMID: 33049085
- DOI: 10.1002/cbin.11482
Bone marrow mesenchymal stem cells inhibit cardiac hypertrophy by enhancing FoxO1 transcription
Abstract
Bone marrow-derived mesenchymal stem cells (BMSCs) have therapeutic potential for certain heart diseases. Previous studies have shown that stem cells inhibit cardiac hypertrophy; however, it is necessary to explore the mechanisms underlying this effect. This study aimed to investigate the possible mechanism underlying the inhibitory effect of BMSCs on cardiomyocyte hypertrophy. We induced cardiomyocyte hypertrophy in cultured rat cells through isoproterenol (ISO) treatment with or without BMSC coculture. A microarray was performed to analyze messenger RNA expression in response to ISO treatment and BMSC coculture. Pathway enrichment analysis showed that the expression of differential genes was closely related to the 5'-adenosine monophosphate-activated protein kinase (AMPK) signaling pathway and that the expression of forkhead box O 1 (FoxO1) was significantly increased in the presence of BMSCs. Furthermore, we determined the expression levels of p-AMPK/AMPK and p-FoxO1/FoxO1 by western blot analysis. The expression of p-AMPK/AMPK was upregulated, whereas that of p-FoxO1/FoxO1 was downregulated upon coculturing with BMSCs. The AMPK-specific antagonist Compound C inhibited the downregulation of p-FoxO1/FoxO1 induced by the BMSC coculture. Furthermore, treatment with the specific FoxO1 antagonist AS1842856 reduced the inhibitory effects of BMSCs on cardiomyocyte hypertrophy in vivo and in vitro. Our present study demonstrates the inhibition of cardiomyocyte hypertrophy by BMSCs, which occurs partly through the AMPK-FoxO1 signaling pathway.
Keywords: 5′-adenosine monophosphate-activated protein kinase; bone marrow-derived mesenchymal stem cells; forkhead box O 1; hypertrophy.
© 2020 International Federation for Cell Biology.
References
REFERENCES
-
- Cai, B., Tan, X., Zhang, Y., Li, X., Wang, X., Zhu, J., Wang, Y., Yang, F., Wang, B., Liu, Y., Xu, C., Pan, Z., Wang, N., Yang, B., & Lu, Y. (2015). Mesenchymal stem cells and cardiomyocytes interplay to prevent myocardial hypertrophy. Stem Cells Translational Medicine, 4, 1425-1435. https://doi.org/10.5966/sctm.2015-0032
-
- Camici, P. G., Tschöpe, C., Di Carli, M. F., Rimoldi, O., & Van Linthout, S. (2020). Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovascular Research, 116, 806-816.
-
- Chen, B., Ma, Y., Meng, R., Xiong, Z., Wang, H., Zeng, J., Liu, C., & Dong, Y. (2010). Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro. Acta Pharmacologica Sinica, 31, 798-804. https://doi.org/10.1038/aps.2010.73
-
- Chen, F., & Xu, B. (2018). GW29-e1834 bone marrow mesenchymal stem cell-derived exosomes attenuates pressure overload induced cardiac remodeling in vivo and in vitro. Journal of the American College of Cardiology, 72, C62-C63.
-
- Dong, H. W., Hang, L. F., & Bao, S. L. (2018). AMPK regulates energy metabolism through the SIRT1 signaling pathway to improve myocardial hypertrophy. European Review for Medical and Pharmacological Sciences, 22, 2757-2766. https://doi.org/10.26355/eurrev_201805_14973
MeSH terms
Substances
Grants and funding
- 81601617/National Natural Science Foundation of China
- 2016- 3-017-YY/Qingdao Science and Technology Development Project
- 2018G SF118057/Shandong Province Key Research and Development Project
- 17-3-3-40-nsh/Qingdao Livelihood Science and Technology Project
- 19-6-2-58-cg/Qingdao Science and Technology Bureau
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous